Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute treatment of migraine with or without aura in adults. It is not useful for prevention. It is taken by mouth.
Common side effects include sleepiness, dizziness, tiredness, and numbness.
Lasmiditan was approved in the United States in October 2019 and became available in February 2020. It was developed by Eli Lilly.